Ad-hoc | 29 May 2001 07:31

Eckert & Ziegler AG english

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Berlin, 29.05.2001. Eckert & Ziegler AG, a specialist for miniaturized, low- level radiation sources for the treatment of cancer and cardiovascular diseases continued it’s growth in term of sales and profits. With sales of 7.2 million EUR, profits before tax and stock options of 574 thousand EUR, results exceeded those of the first quarter of 2000 by 70% and 15% respectively. The nuclear imaging area (+65%), the industrial sources area (+100%) and the oncology segment for radioactive sources (+54%) were the major forces behind the increase in sales compared to the first quarter of 2000. Net income doubled in the first quarter of 2001 and amounted to 497 TEUR; operating income rose by 64% to 837 TEUR. Net earnings per common share increased just short of 90% to 0.15 EUR. For the fiscal year 2001 the company expects sales close to 30 million EUR and EBIT of approximately 6 million EUR. The complete version of the quarterly report is available on the company web- site www.ezag.de The Board of Directors For further information please contact: Karolin Riehle Investor Relations Eckert & Ziegler AG Robert-Rössle-Str. 10 13125 Berlin www.ezag.com Tel.: (+49 30) 94 10 84-138 Fax.: (+49 30) 94 10 84-112 end of ad hoc announcement (c) DGAP 29.05.2001 ——————————————————————————– WKN: 565970; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 290731 Mai 01